How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?

Abstract

FMS-related tyrosine kinase 3 (FLT3) mutations, present in about 25%-30% of acute myeloid leukemia (AML) patients, constitute one of the most frequently detected mutations in these patients. The binding of FLT3L to FLT3 activates the phosphatidylinositol 3-kinase (PI3K) and RAS pathways, producing increased cell proliferation and the inhibition of apoptosis. Two types of FLT3 mutations exist: FLT3-ITD and FLT3-TKD (point mutations in D835 and I836 or deletion of codon I836). A class of drugs, tyrosine-kinase inhibitors (TKI), targeting mutated FLT3, is already available with 1^st and 2^nd generation molecules, but only midostaurin and gilteritinib are currently approved. However, the emergence of resistance or the selection of clones not responding to FLT3 inhibitors has become an important clinical dilemma, as the duration of clinical responses is generally limited to a few months. This review analyzes the insights into mechanisms of resistance to TKI and poses a particular view on the clinical relevance of this phenomenon. Has resistance been overlooked? Indeed, FLT3 inhibitors have significantly contributed to reducing the negative impact of FLT3 mutations on the prognosis of AML patients who are no longer considered at high risk by the European LeukemiaNet (ELN) 2022. Finally, several ongoing efforts to overcome resistance to FLT3-inhibitors will be presented: new generation FLT3 inhibitors in monotherapy or combined with standard chemotherapy, hypomethylating drugs, or IDH1/2 inhibitors, Bcl2 inhibitors; novel anti-human FLT3 monoclonal antibodies (e.g., FLT3/CD3 bispecific antibodies); FLT3-CAR T-cells; CDK4/6 kinase inhibitor (e.g., palbociclib).

Keywords

Acute myeloid Leukemia / FLT3 / gilteritinib / midostaurin / TKI-inhibitor resistance / quizartinib / sorafenib / crenolanib

References

[1] Nakao M,Iwai T.Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.Leukemia1996;10:1911-8

[2] Papaemmanuil E,Bullinger L.Genomic classification and prognosis in acute myeloid leukemia.N Engl J Med2016;374:2209-21 PMCID:PMC4979995

[3] Fröhling S,Breitruck J.Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.Blood2002;100:4372-80

[4] Thiede C,Mohr B.Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.Blood2002;99:4326-35

[5] Kindler T,Fischer T.FLT3 as a therapeutic target in AML: still challenging after all these years.Blood2010;116:5089-102

[6] Park BG,Jang S.Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia.Ann Hematol2013;92:451-7

[7] Stirewalt DL.The role of FLT3 in haematopoietic malignancies.Nat Rev Cancer2003;3:650-65

[8] Gilliland DG.The roles of FLT3 in hematopoiesis and leukemia.Blood2002;100:1532-42

[9] Rusten L,Veiby O.The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro.Blood1996;87:1317-25

[10] Wodnar-Filipowicz A.Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrow.News Physiol Sci2003;18:247-51

[11] Kandeel EZ,Elsharkawy N.Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients.Clin Lymphoma Myeloma Leuk2018;18:541-7

[12] Grafone T,Nicci C.An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment.Oncol Rev2012;6:e8 PMCID:PMC4419636

[13] Fröhling S,Levine RL.Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.Cancer Cell2007;12:501-13

[14] Murphy KM,Hafez MJ.Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.J Mol Diagn2003;5:96-102 PMCID:PMC1907323

[15] Patnaik MM.The importance of FLT3 mutational analysis in acute myeloid leukemia.Leuk Lymphoma2018;59:2273-86

[16] Blätte TJ,Skambraks S.getITD for FLT3-ITD-based MRD monitoring in AML.Leukemia2019;33:2535-9 PMCID:PMC8075860

[17] Perl AE,Cortes JE.Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML.N Engl J Med2019;381:1728-40

[18] Schlenk RF,Bullinger L.Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.Blood2014;124:3441-9

[19] Linch DC,Burnett AK,Gale RE.Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.Blood2014;124:273-6

[20] Angenendt L,Montesinos P.Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts.J Clin Oncol2019;37:2632-42 PMCID:PMC8462529

[21] Pratcorona M,Nomdedéu J.Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.Blood2013;121:2734-8

[22] Gale RE,Allen C.The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.Blood2008;111:2776-84

[23] Döhner H,Grimwade D.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Blood2017;129:424-47 PMCID:PMC5291965

[24] Bacher U,Kern W,Schnittger S.Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.Blood2008;111:2527-37

[25] Whitman SP,Radmacher MD.FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.Blood2008;111:1552-9 PMCID:PMC2214747

[26] Yanada M,Suzuki T,Naoe T.Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.Leukemia2005;19:1345-9

[27] Boddu P,Borthakur G.Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group.Blood Adv2017;1:1546-50 PMCID:PMC5728474

[28] Mead AJ,Hills RK,Burnett AK.FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.Blood2007;110:1262-70

[29] Mead AJ,Hills RK.Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease.Blood2008;112:444-5; author reply 445

[30] Kayser S,Londono MC.Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.Blood2009;114:2386-92

[31] Stone RM,Sanford BL.Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation.N Engl J Med2017;377:454-64 PMCID:PMC5754190

[32] Levis M,Chang K.FLT3 inhibitors added to induction therapy induce deeper remissions.Blood2020;135:75-8

[33] Antar AI,Jabbour E,Bazarbachi A.FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.Leukemia2020;34:682-96

[34] Smith CC,Stecula A,Shah NP.FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.Leukemia2015;29:2390-2 PMCID:PMC4675689

[35] Kim ES.Midostaurin: first global approval.Drugs2017;77:1251-9

[36] Fischer T,Deangelo DJ.Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.J Clin Oncol2010;28:4339-45

[37] Voso MT,Jones D.Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.Blood Adv2020;4:4945-54 PMCID:PMC7556122

[38] Brown EJ.Integrin-associated protein (CD47) and its ligands.Trends Cell Biol2001;11:130-5

[39] Perl AE,Cortes J.Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Lancet Oncol2017;18:1061-75 PMCID:PMC5572576

[40] Dhillon S.Gilteritinib: first global approval.Drugs2019;79:331-9

[41] Perl AE,Podoltsev NA.Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.Blood2022;139:3366-75 PMCID:PMC9197557

[42] Zhang W,Shi YX.Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.J Natl Cancer Inst2008;100:184-98

[43] Metzelder S,Wollmer E.Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.Blood2009;113:6567-71

[44] Metzelder SK,Finck A.High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.Leukemia2012;26:2353-9

[45] Sharma M,Bayraktar UD.Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.Biol Blood Marrow Transplant2011;17:1874-7 PMCID:PMC4061979

[46] Burchert A,Fritz LV.Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN).J Clin Oncol2020;38:2993-3002

[47] Ravandi F,Cortes JE.Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.Leukemia2014;28:1543-5 PMCID:PMC4091714

[48] Röllig C,Hüttmann A.Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.Lancet Oncol2015;16:1691-9

[49] Serve H,Wagner R.Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.J Clin Oncol2013;31:3110-8

[50] Naqvi K.FLT3 inhibitor quizartinib (AC220).Leuk Lymphoma2019;60:1866-76

[51] Cortes J,Döhner H.Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.Lancet Oncol2018;19:889-903 PMCID:PMC8152787

[52] Erba H,Vrhovac R.S100: quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3-ITD+ AML.HemaSphere2022;6:1-2

[53] Molica M.Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours.Expert Rev Hematol2022;15:973-86

[54] Smith CC,Lin KC.Crenolanib is a selective type I pan-FLT3 inhibitor.Proc Natl Acad Sci U S A2014;111:5319-24 PMCID:PMC3986131

[55] Cortes JE,Kadia TM.Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.JCO2016;34:7008-7008

[56] Randhawa JK,Borthakur G.Results of a phase II study of crenolanib in relapsed/refractory acute myeloid leukemia patients (Pts) with activating FLT3 mutations.Blood2014;124:389-389

[57] Döhner K,Jahn N.Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.Blood2020;135:371-80 PMCID:PMC6993016

[58] Desikan SP,DiNardo C,Konopleva M.Resistance to targeted therapies: delving into FLT3 and IDH.Blood Cancer J2022;12:91 PMCID:PMC9184476

[59] Breitenbuecher F,Grundler R.Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.Blood2009;113:4074-7

[60] Zhang H,Schultz AR.Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.Nat Commun2019;10:244 PMCID:PMC6335421

[61] Cortes JE,Martinelli G.Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.Lancet Oncol2019;20:984-97

[62] Ghiaur G.Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment.Hematol Oncol Clin North Am2017;31:681-92 PMCID:PMC5512588

[63] Javidi-Sharifi N,English I.FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells.Elife2019;8

[64] Chang YT,Alonso S.Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.Blood Adv2019;3:908-16 PMCID:PMC6436013

[65] Eguchi M,Kuzume A.Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia.Biomedicines2020;8:245 PMCID:PMC7459983

[66] Smith CC,Perl AE,Rosales M.Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.Blood Adv2022;6:2144-55 PMCID:PMC9006281

[67] Alotaibi AS,Kanagal-Shamanna R.Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors.Blood Cancer Discov2021;2:125-34 PMCID:PMC7935111

[68] Travaglini S,Alfonso V.Characterization of FLT3-ITD(mut) acute myeloid leukemia: molecular profiling of leukemic precursor cells.Blood Cancer J2020;10:85 PMCID:PMC7447750

[69] Schmalbrock LK,Cocciardi S.Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.Blood2021;137:3093-104 PMCID:PMC8233666

[70] Alvarado Y,Luthra R.Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Cancer2014;120:2142-9 PMCID:PMC4124083

[71] Smith CC,Chin CS.Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.Nature2012;485:260-3 PMCID:PMC3390926

[72] Friedman R.The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors.Biochim Biophys Acta Rev Cancer2022;1877:188666

[73] Mizuki M,Halfter H.Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.Blood2000;96:3907-14

[74] McMahon CM,Canaani J.Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia.Cancer Discov2019;9:1050-63

[75] Tarver TC,Rahmat L.Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.Blood Adv2020;4:514-24 PMCID:PMC7013266

[76] Fathi AT,Levis M.Concurrent FLT3 inhibitor and IDH inhibitor therapy in patients with acute myeloid leukemia (AML).Blood2020;136:11-2

[77] Man CH,Ho C.Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.Blood2012;119:5133-43

[78] Stirewalt DL,Meshinchi S.Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.Blood2006;107:3724-6 PMCID:PMC1895777

[79] Schnittger S,Haferlach C,Kern W.Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data.Gene Chromosome Canc2012;51:910-24

[80] Fischer M,Spies-Weisshart B.Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia.Haematologica2017;102:e129-31 PMCID:PMC5395123

[81] Rücker FG,Luck TJ.Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.Leukemia2022;36:90-9 PMCID:PMC8727286

[82] Lee LY,Rajkhowa T.Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.Blood2017;129:257-60 PMCID:PMC5234222

[83] Perl AE,Montesinos P.Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.Blood Cancer J2022;12:84 PMCID:PMC9151663

[84] Pratz KW,Podoltsev NA.AML-256 a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia: final study results.Cl Lymph Myelom Leuk2022;22:S230

[85] Abuasab T,Garcia-manero G.Phase II study of cladribine, idarubicin, cytarabine (CLIA) plus gilteritinib in patients (pts) with FLT3 mutated acute myeloid leukemia (AML).JCO2022;40:e19036-e19036

[86] Konopleva M,Pratz KW.Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naïve acute myeloid leukemia.Clin Cancer Res2022;28:2744-52 PMCID:PMC9365380

[87] Wang ES,Minden MD.Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.Blood2022;140:1845-57

[88] Singh Mali R,DeFilippis RA.Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.Haematologica2021;106:1034-46 PMCID:PMC8017817

[89] Yamatani K,Saito K.Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.Transl Oncol2022;18:101354

[90] Daver N,Maly J.Venetoclax in combination with gilteritinib demonstrates molecular clearance of FLT3 mutation in relapsed/refractory FLT3-mutated acute myeloid leukemia.Blood2021;138:691-691

[91] Maiti A,Daver NG.Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.Blood Cancer J2021;11:25 PMCID:PMC7873265

[92] Hofmann M,Nübling T.Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia.Leukemia2012;26:1228-37

[93] Jetani H,Nerreter T.CAR T-cells targeting FLT3 have potent activity against FLT3^-ITD⁺ AML and act synergistically with the FLT3-inhibitor crenolanib.Leukemia2018;32:1168-79

[94] Sommer C,Nguyen D.Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery.Mol Ther2020;28:2237-51 PMCID:PMC7544976

[95] Yeung YA,Dettling D.An optimized full-length FLT3/CD3 bispecific antibody demonstrates potent anti-leukemia activity and reversible hematological toxicity.Mol Ther2020;28:889-900 PMCID:PMC7054815

[96] Otto T.The kinase-independent, second life of CDK6 in transcription.Cancer Cell2013;24:141-3 PMCID:PMC3809765

[97] Uras IZ,Scheicher R.Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.Blood2016;127:2890-902 PMCID:PMC4920675

[98] Döhner H,Appelbaum FR.Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Blood2022;140:1345-77

[99] Day JW,Gupta R,Wilson AJ.Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy.Leuk Res Rep2022;17:100291 PMCID:PMC8844896

[100] Zhang Z,Hashimoto D.Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant2022;57:775-80

[101] Martínez-Cuadrón D,Mariz J.Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia.Cancers2022;14:2817 PMCID:PMC9179309